DAVIS, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, is pleased to announce that Regalia, its flagship biofungicide for control of powdery mildew and other plant diseases, has been approved for use on Cannabis by the Colorado, Oregon, Nevada, and Washington Departments of Agriculture.
Regalia CG is a reduced-risk, plant extract-based biofungicide. The Cannabis-ready product will be available in May of 2018 in either one quart or one-gallon container sizes. Field and greenhouse efficacy trials have consistently shown that Regalia CG offers a superior level of powdery mildew control in Cannabis and Hemp. Regalia also controls Botrytis gray mold and leaf spots as well.
Regalia CG is both USDA National Organic Program certified and Organic Materials Research Institute (OMRI) listed for use in organic farming. As a reduced-risk fungicide, Regalia CG has minimal re-entry intervals and pre-harvest intervals, meaning the product can be applied to crops right up to the day of harvest without presenting worker safety concerns. Additionally, it is exempt from food tolerance requirements in the United States and Canada, which means that the use of Regalia does not trigger pesticide residue risk concerns for workers and consumers.
Regalia’s unique “Induced Systemic Response” (ISR) mode of action, in which the application of Regalia activates a plant’s own immune response mechanism, provides significant plant health benefits. After hundreds of field trials in many different crops, including berries, tomatoes, cut flowers, potatoes, corn and soybeans, the use of Regalia has demonstrated a strong track record of improving crop yields and/or quality, while providing increased grower return on investment.
Furthermore, in some instances, Regalia’s ISR effect has yielded additional marketable benefits for some crops, most notably, with the production of flavor-enhancing phenolics in some wine grape varieties and the boost in nutritionally important proteins in alfalfa and wheat and brix (sugar) in sugarcane. A future focus of MBI’s research will be to evaluate the effect that Regalia’s unique ISR mechanism may have on terpene and cannabinoid compounds in Cannabis.
“In recent years, Regalia has been considered the go-to product for powdery mildew control in the Cannabis industry,” said Kyle Stamback, Director of Cultivation at NorthWestGrown i502 and Owner of Lean Cultivation LLC. “Regalia is the staple of my IPM regiment because of its ISR capabilities. Regalia puts my mind at ease as I think about the potentially harmful pathogens infecting my plants. I apply Regalia as a foliar spray and through my hydroponic nutrient injectors.
“When using Regalia on a consistent schedule, I have documented increased vigor and stalk size. Due to the overall plant health, my yields have been remarkable. As a result of tank mixing Regalia and other great products offered by Marrone Bio, my plants have never been healthier and my IPM has never been simpler.”
“Marrone Bio appreciates the guidance and support of many in the Cannabis industry, including state agencies overseeing legal Cannabis production, in developing Regalia CG for this rapidly growing market,” stated Lisa Malabad, Cannabis Segment Lead at Marrone Bio Innovations. “We are pleased that the Colorado, Oregon, Nevada and Washington Departments of Agriculture determined that Regalia CG meets the state’s criteria for use on Cannabis, and we look forward to working with growers and distributors to serve these exciting new markets with our existing product portfolio as well as our future innovations.”
About Marrone Bio Innovations
Bio With Bite.
Marrone Bio Innovations, Inc. (NASDAQ:MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. MBI’s effective and environmentally responsible pest management solutions help customers operate more sustainably while uniquely improving plant health and increasing crop yields. MBI’s currently available commercial products are Regalia®, Grandevo®, Venerate®, Majestene®, Haven® StargusTM and AmplitudeTM, ZeltoTM and Zequanox®. MBI also distributes Bio-tam 2.0® for Isagro USA and Jet-Ag® for Jet Harvest in most regions of the U.S.
Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions that support a better tomorrow for both farmers, turf managers and consumers around the globe. For more information, please visit www.marronebio.com.
Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the potential of Regalia CG and other MBI products in the US and Canada, market projections, including the potential benefits of Regalia CG. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.